BofA Securities made an adjustment to Huntington Ingalls Industries' (NYSE:HII) financial outlook, reducing the price target ...

Using CRISPR technology, scientists uncovered genes that control C-A-G genetic stumbles in Huntington's disease ...

Harness Therapeutics Ltd. has raised fresh financing to further develop its technology for upregulating the translation of ...

While the company's Mission Technologies division has been performing well, it is not expected to be the primary driver of Huntington Ingalls (NYSE:HII)' stock. The firm's shares appear inexpensive ...

Barclays lowered the firm’s price target on HII (HII) to $200 from $220 and keeps an Equal Weight rating on the shares.Maximize Your Portfolio ...

Baird raised the firm’s price target on Huntington Bancshares (HBAN) to $18 from $17 and keeps a Neutral rating on the shares. The firm attended the company’s investor day where long-term ...

On Tuesday, DA Davidson adjusted its outlook on Huntington Bancshares (NASDAQ:HBAN), currently trading at $17.01, by reducing the price target to $20.50 from the previous $21.50. Despite the price ...